An independent appraisal and re-analysis of hydroxychloroquine treatment trial for COVID-19

Swiss Med Wkly. 2020 Apr 29:150:w20262. doi: 10.4414/smw.2020.20262. eCollection 2020 Apr 20.

Authors

Katheron Intson¹, Sachin Kumar¹, Amy Botta², Rachael Neckles³, Connie Leung⁴, Ali Jawaid⁵

Affiliations

¹ Faculty of Medicine, University of Toronto, Toronto ON, Canada.
² Faculty of Science, York University, Toronto ON, Canada.
³ Department of Biomolecular Sciences, Boise State University, Boise ID, USA.
⁴ Faculty of Medicine, University of British Columbia, Vancouver BC, Canada.
⁵ Brain Research Institute, University of Zurich, Switzerland / Nencki Institute-EMBL Centre for Excellence in Neural Plasticity and Brain Disorders, Warsaw, Poland.

PMID: 32347963
DOI: 10.4414/smw.2020.20262

No abstract available

MeSH terms

Adult
Azithromycin / therapeutic use
Betacoronavirus
COVID-19
COVID-19 Drug Treatment
Clinical Trials as Topic*
Coronavirus Infections / drug therapy*
Data Accuracy
Drug Synergism
Drug Therapy, Combination
France
Humans
Hydroxychloroquine / therapeutic use*
Middle Aged
Pandemics
Pneumonia, Viral / drug therapy*
Research Design
SARS-CoV-2

Substances

Hydroxychloroquine
Azithromycin